サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1514147

抗菌薬の世界市場

Antibacterial Drugs

出版日
ページ情報
英文 244 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
抗菌薬の世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 244 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

抗菌薬の世界市場は2030年までに586億米ドルに達する見込み

2023年に449億米ドルと推定された抗菌薬の世界市場は、分析期間2023-2030年にCAGR 3.9%で成長し、2030年には586億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるB-ラクタム薬剤クラス別は、CAGR 4.1%を記録し、分析期間終了時には354億米ドルに達すると予測されます。マクロライド薬剤クラス別の成長率は、分析期間中CAGR 4.4%と推定されます。

米国市場は122億米ドルと推定、中国はCAGR 6.5%で成長予測

米国の抗菌薬市場は2023年に122億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに121億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは6.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.0%と3.2%と予測されています。欧州では、ドイツがCAGR 2.6%で成長すると予測されています。

抗菌薬-主要動向と促進要因

一般に抗生物質として知られる抗菌薬は、細菌感染症の治療に不可欠であり、現代医学の要です。これらの薬剤は、その作用機序により、細菌を死滅させる（殺菌性）か、細菌の増殖を抑制する（静菌性）かのいずれかで作用します。抗菌薬は、ペニシリン系、セファロスポリン系、テトラサイクリン系、マクロライド系、フルオロキノロン系、アミノグリコシド系などいくつかのカテゴリーに分類され、それぞれが特定の種類の細菌を標的としています。例えば、ペニシリン系とセファロスポリン系は細菌の細胞壁合成を阻害し、テトラサイクリン系はタンパク質合成を阻害します。これらの薬剤は、軽度の皮膚感染症や呼吸器感染症から、敗血症、細菌性髄膜炎、結核などの重篤な症状まで、幅広い細菌感染症の治療に使用されています。抗生物質の発見と広範な使用は、細菌感染に伴う罹患率と死亡率を劇的に減少させ、医学史上最も重要な進歩のひとつとなった。

抗菌薬市場における重要な動向は、細菌が抗生物質の効果に耐えるメカニズムを進化させる、抗生物質耐性の問題の増加です。この現象は、複数の抗生物質に耐性を持ち、公衆衛生に深刻な脅威をもたらす「スーパーバグ」の台頭につながっています。世界保健機関（WHO）は、抗生物質耐性を世界の健康上の脅威のトップに挙げています。この危機に対応するため、新しい抗生物質や代替療法の開発に重点が置かれています。細菌に特異的に感染して殺すウイルスであるバクテリオファージや、細菌膜を破壊する抗菌ペプチドの研究が進められています。また、耐性菌の主な原因となる過剰使用や誤用を減らすことを目的としたスチュワードシップ・プログラムを通じて、抗生物質の責任ある使用を促進する取り組みも行われています。これらのプログラムは、適切な抗生物質使用の重要性と耐性菌がもたらす潜在的な影響について、ヘルスケア専門家と一般市民を教育することに重点を置いています。製薬会社や研究機関は、新規抗菌薬の発見や既存薬の耐性株対策への再利用を目的とした革新的な研究に多額の投資を行っており、有効な治療法の確保に努めています。

抗菌薬市場の成長は、創薬技術の進歩、細菌感染症の流行増加、抗生物質耐性に対する意識の高まりなど、いくつかの要因によって牽引されています。ハイスループット・スクリーニング、ゲノミクス、バイオインフォマティクスなどの技術進歩により、新規抗生物質の発見が加速し、耐性菌メカニズムの解明が進んでいます。これらの技術により、研究者は新たな創薬標的を特定し、より効果的な抗菌薬を開発することができます。人口の高齢化、入院の増加、慢性疾患の罹患率の上昇などの要因によって悪化する細菌感染症の有病率の増加は、効果的な抗菌治療薬に対する需要を引き続き牽引しています。さらに、公衆衛生への取り組みや教育キャンペーンにより、抗生物質耐性の危険性に対する認識が高まり、より効果的な新しい治療薬への需要が高まっています。細菌感染や耐性パターンを特定するための迅速診断ツールの市場開拓も、より的を絞った効果的な治療を可能にするため、市場の成長を後押ししています。さらに、政府や非政府組織による研究開発活動への資金援助や、新規抗生物質の迅速な審査プロセスなどの規制上の優遇措置が、市場のイノベーションを促進しています。全体として、これらの要因が相まって、抗菌薬市場の持続的な成長と技術革新が促進され、細菌感染との闘いにおける重要な医薬品の継続的な有効性が確保されています。

調査対象企業の例（注目の124社）

  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6168

Global Antibacterial Drugs Market to Reach US$58.6 Billion by 2030

The global market for Antibacterial Drugs estimated at US$44.9 Billion in the year 2023, is expected to reach US$58.6 Billion by 2030, growing at a CAGR of 3.9% over the analysis period 2023-2030. B-lactams Drug Class, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$35.4 Billion by the end of the analysis period. Growth in the Macrolides Drug Class segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$12.2 Billion While China is Forecast to Grow at 6.5% CAGR

The Antibacterial Drugs market in the U.S. is estimated at US$12.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$12.1 Billion by the year 2030 trailing a CAGR of 6.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Antibacterial Drugs - Key Trends and Drivers

Antibacterial drugs, commonly known as antibiotics, are essential in the treatment of bacterial infections and are a cornerstone of modern medicine. These drugs work by either killing bacteria (bactericidal) or inhibiting their growth (bacteriostatic), depending on their mechanism of action. Antibacterial drugs are classified into several categories, including penicillins, cephalosporins, tetracyclines, macrolides, fluoroquinolones, and aminoglycosides, each targeting specific types of bacteria. For example, penicillins and cephalosporins disrupt bacterial cell wall synthesis, while tetracyclines inhibit protein synthesis. These drugs are used to treat a wide range of bacterial infections, from minor skin infections and respiratory tract infections to more severe conditions such as sepsis, bacterial meningitis, and tuberculosis. The discovery and widespread use of antibiotics have dramatically reduced the morbidity and mortality associated with bacterial infections, representing one of the most significant advancements in medical history.

A significant trend in the antibacterial drugs market is the increasing problem of antibiotic resistance, where bacteria evolve mechanisms to withstand the effects of antibiotics. This phenomenon has led to the rise of "superbugs" which are resistant to multiple antibiotics and pose a severe threat to public health. The World Health Organization (WHO) has identified antibiotic resistance as one of the top global health threats. In response to this crisis, there is a growing emphasis on developing new antibiotics and alternative therapies. Research is being directed towards bacteriophages, viruses that specifically infect and kill bacteria, and antimicrobial peptides, which can disrupt bacterial membranes. Efforts are also being made to promote the responsible use of antibiotics through stewardship programs aimed at reducing overuse and misuse, which are primary drivers of resistance. These programs focus on educating healthcare professionals and the public about the importance of appropriate antibiotic use and the potential consequences of resistance. Pharmaceutical companies and research institutions are investing heavily in innovative research to discover novel antibacterial agents and repurpose existing drugs to combat resistant strains, ensuring that effective treatments remain available.

The growth in the antibacterial drugs market is driven by several factors, including technological advancements in drug discovery, the increasing prevalence of bacterial infections, and the rising awareness of antibiotic resistance. Technological advancements, such as high-throughput screening, genomics, and bioinformatics, have accelerated the discovery of new antibiotics and enhanced the understanding of bacterial resistance mechanisms. These technologies enable researchers to identify novel drug targets and develop more effective antibacterial agents. The growing prevalence of bacterial infections, exacerbated by factors such as aging populations, increased hospitalizations, and the rising incidence of chronic diseases, continues to drive demand for effective antibacterial treatments. Additionally, public health initiatives and educational campaigns have raised awareness about the dangers of antibiotic resistance, leading to increased demand for new and more effective antibacterial drugs. The development of rapid diagnostic tools to identify bacterial infections and resistance patterns is also propelling market growth, as these tools enable more targeted and effective treatments. Furthermore, the support from government and non-government organizations in funding research and development activities, as well as regulatory incentives such as expedited review processes for new antibiotics, is fostering innovation in the market. Overall, the combination of these factors is driving sustained growth and innovation in the antibacterial drugs market, ensuring the continued effectiveness of these critical medicines in the fight against bacterial infections.

Select Competitors (Total 124 Featured) -

  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Antibacterial Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Bacterial Infections Expands Addressable Market Opportunity for Antibacterial Drugs
    • Advances in Drug Discovery Technologies Propel Growth in the Antibacterial Drugs Market
    • Increasing Antibiotic Resistance Throws the Spotlight on New Drug Development
    • Development of Novel Antibiotics Strengthens Business Case for Innovative Treatments
    • High-Throughput Screening Techniques Accelerate Identification of New Antibacterial Compounds
    • Genomic Research Spurs Growth by Uncovering New Drug Targets
    • Integration of Bioinformatics in Drug Development Expands Market Potential
    • Public Health Initiatives Drive Adoption of Responsible Antibiotic Use Programs
    • Rising Awareness of Antibiotic Resistance Generates Demand for New Treatments
    • Increasing Prevalence of Hospital-Acquired Infections Sustains Market Growth
    • Expansion of Rapid Diagnostic Tools Enhances Market for Targeted Antibacterial Therapies
    • Growth in Aging Population Expands Need for Effective Antibacterial Drugs
    • Advances in Bacteriophage Therapy Generate Opportunities for Alternative Treatments
    • Growing Use of Antimicrobial Peptides Propels Market Growth
    • Evolving Healthcare Infrastructure in Emerging Markets Expands Market Reach for Antibacterial Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antibacterial Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antibacterial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antibacterial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Antibacterial Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for B-lactams by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for B-lactams by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for B-lactams by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Macrolides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Macrolides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Macrolides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Quinolones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Quinolones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Quinolones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Tetracyclines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Tetracyclines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Tetracyclines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Aminoglycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Drug Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • JAPAN
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CHINA
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • EUROPE
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Antibacterial Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Antibacterial Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Antibacterial Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • FRANCE
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • GERMANY
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Antibacterial Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Antibacterial Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Antibacterial Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • INDIA
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: India 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Antibacterial Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Antibacterial Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Antibacterial Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Antibacterial Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Antibacterial Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Antibacterial Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • AFRICA
    • Antibacterial Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Antibacterial Drugs by Drug Class - B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Value Sales for B-lactams, Macrolides, Quinolones, Tetracyclines, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Antibacterial Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Antibacterial Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030

IV. COMPETITION